Filing Details

Accession Number:
0001399529-21-000029
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-02-04 17:11:56
Reporting Period:
2021-02-02
Accepted Time:
2021-02-04 17:11:56
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1399529 Dicerna Pharmaceuticals Inc DRNA Pharmaceutical Preparations (2834) 205993609
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1813985 M. Regina Paglia C/O Dicerna Pharmaceuticals, Inc.
75 Hayden Avenue
Lexington MA 02421
Chief Human Resources Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-02-02 4,431 $12.93 4,431 No 4 M Direct
Common Stock Disposition 2021-02-02 4,431 $24.00 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (Right to Buy) Disposition 2021-02-02 4,431 $0.00 4,431 $12.93
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
141,138 2029-02-28 No 4 M Direct
Footnotes
  1. The Reporting Person sold an aggregate of 4,431 shares of Common Stock on February 2, 2021(the "Shares Sold") as reported in this Form 4. The Shares Sold represent 1.48% of 300,319 shares of Common Stock, which is the number of shares of Common Stock owned by the Reporting Person prior to the Shares Sold transaction reported in this Form 4, as well as shares issuable upon exercise or settlement of vested and unvested options and restricted stock units held by the Reporting Person as of the date of this report.
  2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 16, 2020.
  3. The option vests 25% on the first year anniversary of the vesting start date of February 19, 2019 and the remaining 75% vests in 36 substantially equal monthly installments thereafter, subject in each case to the Reporting Person's continued service with the Issuer through each applicable vesting date.